Co-founded by Dr. Saar Gill, PhD, a physician-scientist at the University of Pennsylvania, and Bruce Peacock, a renowned biotech veteran, Interius is a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery.

Interius is developing a platform to enable an efficacious, potentially safer, and more accessible set of therapies to address diseases driven by single gene mutations, as well as complex diseases, such as cancers. Interius is initially focused on treating hematologic malignancies by leveraging its novel gene delivery platform to generate CAR T cells directly in vivo.

This therapeutic approach bypasses the need for ex vivo cell manipulations and the potentially toxic preconditioning chemotherapy required for standard CAR T-cell treatments, the company said. Interius is also using the platform to develop applications beyond immuno-oncology that address diseases not amenable to current gene therapy modalities, the company noted.

Interius BioTherapeutics raises $76M for GCT platform
Interius BioTherapeutics has raised $76 million in fundraising to advance its gene and cell therapy (GCT) platform.